NKG2A inhibits invariant NKT cell activation in hepatic injury

Journal of Immunology

Volumn 182, Issue 1, 2009, Pages 250-258

  Kawamura, Toshihiko ^a   Takeda, Kazuyoshi ^b,c   Kaneda, Hiroshi ^b   Matsumoto, Hiroaki ^a   Hayakawa, Yoshihiro ^c   Raulet, David H ^d   Ikarashi, Yoshinori ^e   Kronenberg, Mitchell ^f   Yagita, Hideo ^b   Kinoshita, Katsuyuki ^b   Abo, Toru ^a   Okumura, Ko ^b   Smyth, Mark J ^c  

^a NIIGATA UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^f LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD94 ANTIGEN; CONCANAVALIN A; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 20D5; NATURAL KILLER CELL RECEPTOR NKG2A; PERFORIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; GROWTH INHIBITOR; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY C; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE EXACERBATION; DISEASE SEVERITY; LIVER INJURY; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL DEPLETION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; DBA MOUSE; DOWN REGULATION; DRUG ANTAGONISM; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TOXIC HEPATITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CONCANAVALIN A; DOWN-REGULATION; GROWTH INHIBITORS; HEPATITIS, TOXIC; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY D; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION;

EID: 59849109974     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.1.250     Document Type: Article

References (49)

1. Kronenberg, M., and L. Gapin. 2002. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2: 557-568.
2. Taniguchi, M., M. Harada, S. Kojo, T. Nakayama, and H. Wakao. 2003. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21: 483-513.
3. De Libero, G., and L. Mori. 2005. Recognition of lipid antigens by T cells. Nat. Rev. Immunol. 5: 485-496.
4. Kaneko, Y., M. Harada, T. Kawano, M. Yamashita, Y. Shibata, F. Gejyo, T. Nakayama, and M. Taniguchi. 2000. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J. Exp. Med. 191: 105-114.
5. Takeda, K., Y. Hayakawa, L. Van Kaer, H. Matsuda, H. Yagita, and K. Okumura. 2000. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. USA 97: 5498-5503.
6. Osman, Y., T. Kawamura, T. Naito, K. Takeda, L. Van Kaer, K. Okumura, and T. Abo. 2000. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur. J. Immunol. 30: 1919-1928.
7. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274.
8. Vivier, E., and N. Anfossi. 2004. Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat. Rev. Immunol. 4: 190-198.
9. Vance, R. E., A. M. Jamieson, and D. H. Raulet. 1999. Recognition of the class Ib molecule Qa-1b by putative activating receptors CD94/NKG2C and CD94/ NKG2E on mouse natural killer cells. J. Exp. Med. 190: 1801-1812.
10. Vance, R. E., A. M. Jamieson, D. Cado, and D. H. Raulet. 2002. Implications of CD94 deficiency and monoallelic NKG2A expression for natural killer cell development and repertoire formation. Proc. Natl. Acad. Sci. USA 99: 868-873.
11. Vance, R. E., J. R. Kraft, J. D. Altman, P. E. Jensen, and D. H. Raulet. 1998. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1b. J. Exp. Med. 188: 1841-1848.
12. Lu, L., M. B. Werneck, and H. Cantor. 2006. The immunoregulatory effects of Qa-1. Immunol. Rev. 212: 51-59.
13. Noble, A., Z. S. Zhao, and H. Cantor. 1998. Suppression of immune responses by CD8 cells. II. Qa-1 on activated B cells stimulates CD8 cell suppression of T helper 2 responses. J. Immunol. 160: 566-571.
14. Ota, T., K. Takeda, H. Akiba, Y. Hayakawa, K. Ogasawara, Y. Ikarashi, S. Miyake, H. Wakasugi, T. Yamamura, M. Kronenberg, et al. 2005. IFN-γ-mediated negative feedback regulation of NKT-cell function by CD94/NKG2. Blood 106: 184-192.
15. Uldrich, A. P., N. Y. Crowe, K. Kyparissoudis, D. G. Pellicci, Y. Zhan, A. M. Lew, P. Bouillet, A. Strasser, M. J. Smyth, and D. I. Godfrey. 2005. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175: 3092-3101.
16. Matsuda, J. L., O. V. Naidenko, L. Gapin, T. Nakayama, M. Taniguchi, C. R. Wang, Y. Koezuka, and M. Kronenberg. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192: 741-754.
17. Takeda, K., N. Yamaguchi, H. Akiba, Y. Kojima, Y. Hayakawa, J. E. Tanner, T. J. Sayers, N. Seki, K. Okumura, H. Yagita, and M. J. Smyth. 2004. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199: 437-448.
18. Kataoka, T., N. Shinohara, H. Takayama, K. Takaku, S. Kondo, S. Yonehara, and K. Nagai. 1996. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 156: 3678-3686.
19. Takeda, K., and G. Dennert. 1993. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J. Exp. Med. 177: 155-164.
20. Watanabe, Y., M. Morita, and T. Akaike. 1996. Concanavalin A induces perforin-mediated but not Fas-mediated hepatic injury. Hepatology 24: 702-710.
21. + T cells for concanavalin A-induced hepatic injury in mice. J. Immunol. 159: 1537-1542.
22. Wald, O., I. D. Weiss, H. Wald, H. Shoham, Y. Bar-Shavit, K. Beider, E. Galun, L. Weiss, L. Flaishon, I. Shachar, et al. 2006. IFN-γ acts on T cells to induce NK cell mobilization and accumulation in target organs. J. Immunol. 176: 4716-4729.
23. Hayakawa, Y., K. Takeda, H. Yagita, L. Van Kaer, I. Saiki, and K. Okumura. 2001. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J. Immunol. 166: 6012-6018.
24. Kaneda, H., K. Takeda, T. Ota, Y. Kaduka, H. Akiba, Y. Ikarashi, H. Wakasugi, M. Kronenberg, K. Kinoshita, H. Yagita, and K. Okumura. 2005. ICOS costimulates invariant NKT cell activation. Biochem. Biophys. Res. Commun. 327: 201-207.
25. Perrin, P. J., T. A. Davis, D. S. Smoot, R. Abe, C. H. June, and K. P. Lee. 1997. Mitogenic stimulation of T cells reveals differing contributions for B7-1 (CD80) and B7-2 (CD86) costimulation. Immunology 90: 534-542.
26. Eberl, G., and H. R. MacDonald. 1998. Rapid death and regeneration of NKT cells in anti-CD3ε- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity 9: 345-353.
27. Hayakawa, Y., K. Takeda, H. Yagita, S. Kakuta, Y. Iwakura, L. Van Kaer, I. Saiki, and K. Okumura. 2001. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur. J. Immunol. 31: 1720-1727.
28. Wilson, M. T., C. Johansson, D. Olivares-Villagomez, A. K. Singh, A. K. Stanic, C. R. Wang, S. Joyce, M. J. Wick, and L. Van Kaer. 2003. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl. Acad. Sci. USA 100: 10913-10918.
29. Crowe, N. Y., A. P. Uldrich, K. Kyparissoudis, K. J. Hammond, Y. Hayakawa, S. Sidobre, R. Keating, M. Kronenberg, M. J. Smyth, and D. I. Godfrey. 2003. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J. Immunol. 171: 4020-4027.
30. Harada, M., K. Seino, H. Wakao, S. Sakata, Y. Ishizuka, T. Ito, S. Kojo, T. Nakayama, and M. Taniguchi. 2004. Down-regulation of the invariant Vα14 antigen receptor in NKT cells upon activation. Int. Immunol. 16: 241-247.
31. Maeda, M., S. Lohwasser, T. Yamamura, and F. Takei. 2001. Regulation of NKT cells by Ly49: analysis of primary NKT cells and generation of NKT cell line. J. Immunol. 167: 4180-4186.
32. Ito, K., M. Karasawa, T. Kawano, T. Akasaka, H. Koseki, Y. Akutsu, E. Kondo, S. Sekiya, K. Sekikawa, M. Harada, et al. 2000. Involvement of decidual Vα14 NKT cells in abortion. Proc. Natl. Acad. Sci. USA 97: 740-744.
33. Tupin, E., A. Nicoletti, R. Elhage, M. Rudling, H. G. Ljunggren, G. K. Hansson, and G. P. Berne. 2004. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 199: 417-422.
34. Crowe, N. Y., J. M. Coquet, S. P. Berzins, K. Kyparissoudis, R. Keating, D. G. Pellicci, Y. Hayakawa, D. I. Godfrey, and M. J. Smyth. 2005. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202: 1279-1288.
35. Mizuhara, H., E. O'Neill, N. Seki, T. Ogawa, C. Kusunoki, K. Otsuka, S. Satoh, M. Niwa, H. Senoh, and H. Fujiwara. 1994. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J. Exp. Med. 179: 1529-1537.
36. Nicoletti, F., R. Di Marco, P. Zaccone, A. Salvaggio, G. Magro, K. Bendtzen, and P. Meroni. 2000. Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-γ-dependent mechanism. Hepatology 32: 728-733.
37. -/- mice: role for IFN-γ in activating apoptosis of hepatocytes. J. Immunol. 159: 1418-1428.
38. Ksontini, R., D. B. Colagiovanni, M. D. Josephs, C. K. Edwards, III, C. L. Tannahill, C. C. Solorzano, J. Norman, W. Denham, M. Clare-Salzler, S. L. MacKay, and L. L. Moldawer. 1998. Disparate roles for TNF-α and Fas ligand in concanavalin A-induced hepatitis. J. Immunol. 160: 4082-4089.
39. Tagawa, Y., S. Kakuta, and Y. Iwakura. 1998. Involvement of Fas/Fas ligand system-mediated apoptosis in the development of concanavalin A-induced hepatitis. Eur. J. Immunol. 28: 4105-4113.
40. Hu, D., K. Ikizawa, L. Lu, M. E. Sanchirico, M. L. Shinohara, and H. Cantor. 2004. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat. Immunol. 5: 516-523.
41. Kitamura, H., K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, et al. 1999. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189: 1121-1128.
42. Carnaud, C., D. Lee, O. Donnars, S. H. Park, A. Beavis, Y. Koezuka, and A. Bendelac. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163: 4647-4650.
43. Hahn, S., R. Gehri, and P. Erb. 1995. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol. Rev. 146: 57-79.
44. neg iNKT cell population involved in airway neutrophilia. J. Exp. Med. 204: 995-1001.
45. - NKT cell population. Proc. Natl. Acad. Sci. USA 105: 11287-11292.
46. Weaver, C. T., R. D. Hatton, P. R. Mangan, and L. E. Harrington. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25: 821-852.
47. Smyth, M. J., and D. I. Godfrey. 2000. NKT cells and tumor immunity - a double-edged sword. Nat. Immunol. 1: 459-460.
48. Smyth, M. J., N. Y. Crowe, Y. Hayakawa, K. Takeda, H. Yagita, and D. I. Godfrey. 2002. NKT cells- conductors of tumor immunity? Curr. Opin. Immunol. 14: 165-171.
49. Mars, L. T., J. Novak, R. S. Liblau, and A. Lehuen. 2004. Therapeutic manipulation of iNKT cells in autoimmunity: modes of action and potential risks. Trends Immunol. 25: 471-476.